Civil Litigation
May 20, 2019
Novel strategy doesn’t pay for Allergan in false advertising case
In what defense attorneys are calling a novel trial strategy, pharmaceutical giant Allergan USA Inc. won $48,500 instead of the $7.2 million in damages and $54 million in disgorged profits it sought in its false advertising suit against Imprimis Pharmaceuticals Inc.
In what defense attorneys are calling a novel trial strategy, pharmaceutical giant Allergan USA Inc. won $48,500 instead of the $7.2 million in damages and $54 million in disgorged profits it sought in its false advertising suit against Imprimis Pharmaceuticals Inc.
Represented by Keith Wesley of Browne George Ross LLP and Daniel Rasmussen of Payne & Fears LLP, Imprimis was able to obtain the mild jury verdict despite U.S. Distri...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
Enewsletter Sign-up
Related Content
Intellectual Property, Government
Bill to ban delays in generic drug access passes the Assembly
By Malcolm Maclachlan
